Richard Lorber

718 total citations
16 papers, 532 citations indexed

About

Richard Lorber is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Immunology and Allergy. According to data from OpenAlex, Richard Lorber has authored 16 papers receiving a total of 532 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Physiology, 12 papers in Pulmonary and Respiratory Medicine and 12 papers in Immunology and Allergy. Recurrent topics in Richard Lorber's work include Asthma and respiratory diseases (14 papers), Allergic Rhinitis and Sensitization (12 papers) and Respiratory and Cough-Related Research (11 papers). Richard Lorber is often cited by papers focused on Asthma and respiratory diseases (14 papers), Allergic Rhinitis and Sensitization (12 papers) and Respiratory and Cough-Related Research (11 papers). Richard Lorber collaborates with scholars based in United States, Canada and Belgium. Richard Lorber's co-authors include Melvyn Danzig, Eli O. Meltzer, S. James Zinreich, William W. Busse, B.Lauren Charous, Luis M. Salmun, L. DuBuske, William E. Berger, Carlos E. Baena‐Cagnani and Paul Stryszak and has published in prestigious journals such as CHEST Journal, Journal of Allergy and Clinical Immunology and Allergy.

In The Last Decade

Richard Lorber

16 papers receiving 482 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Richard Lorber United States	12	373	326	165	147	76	16	532
Ji-Ho Lee South Korea	13	124 0.3×	205 0.6×	11 0.1×	160 1.1×	48 0.6×	53	412
Kentaro Watai Japan	9	105 0.3×	205 0.6×	46 0.3×	140 1.0×	25 0.3×	34	310
Xinni Xu Singapore	8	60 0.2×	69 0.2×	93 0.6×	67 0.5×	58 0.8×	25	245
Burcin Uygungil United States	7	99 0.3×	231 0.7×	5 0.0×	70 0.5×	65 0.9×	13	454
A B Löfroos Sweden	10	41 0.1×	599 1.8×	17 0.1×	565 3.8×	39 0.5×	10	660
M. Rosario Caballero United Kingdom	8	217 0.6×	223 0.7×	5 0.0×	41 0.3×	76 1.0×	14	509
J.V. Fahy United States	9	71 0.2×	373 1.1×	3 0.0×	382 2.6×	21 0.3×	18	504
Janine Beale United Kingdom	4	78 0.2×	194 0.6×	5 0.0×	70 0.5×	63 0.8×	7	339
Anna Padovani Italy	7	46 0.1×	257 0.8×	10 0.1×	134 0.9×	40 0.5×	13	417
Brian Hanson United States	9	44 0.1×	122 0.4×	5 0.0×	60 0.4×	205 2.7×	28	462

Countries citing papers authored by Richard Lorber

Since Specialization

Citations

This map shows the geographic impact of Richard Lorber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Lorber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Lorber more than expected).

Fields of papers citing papers by Richard Lorber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Lorber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Lorber. The network helps show where Richard Lorber may publish in the future.

Co-authorship network of co-authors of Richard Lorber

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Lorber. A scholar is included among the top collaborators of Richard Lorber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Lorber. Richard Lorber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Bousquet, Philippe‐Jean, Claus Bachert, Giorgio Walter Canonica, et al.. (2010). Efficacy of Desloratadine in Persistent Allergic Rhinitis – A GA<sup>2</sup>LEN Study. International Archives of Allergy and Immunology. 153(4). 395–402. 36 indexed citations

Sullivan, Patrick W., Prakash Navaratnam, Richard Lorber, & Tulin Shekar. (2010). The cost-effectiveness of treatment with desloratadine in patients with persistent allergic rhinitis. Current Medical Research and Opinion. 26(6). 1389–1397. 2 indexed citations

Bousquet, Jean, Claus Bachert, Giorgio Walter Canonica, et al.. (2009). Efficacy of desloratadine in intermittent allergic rhinitis: a GA²LEN study. Allergy. 64(10). 1516–1523. 43 indexed citations

Prenner, Bruce M., Rosalía Ballona, Ricardo Cardona, et al.. (2006). Safety of Desloratadine Syrup in Children Six Months to Younger Than 2 Years of Age: A Randomized, Double-Blinded, Placebo-Controlled Study. Pediatric Asthma Allergy & Immunology. 19(2). 91–99. 8 indexed citations

Prenner, Bruce M., Kenneth Kim, Samir K. Gupta, et al.. (2006). Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety. Expert Opinion on Drug Safety. 5(2). 211–223. 17 indexed citations

Baena‐Cagnani, Carlos E., William E. Berger, L. DuBuske, et al.. (2003). Comparative Effects of Desloratadine versus Montelukast on Asthma Symptoms and Use of β<sub>2</sub>-Agonists in Patients with Seasonal Allergic Rhinitis and Asthma. International Archives of Allergy and Immunology. 130(4). 307–313. 81 indexed citations

Salmun, Luis M. & Richard Lorber. (2002). 24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139]. BMC Family Practice. 3(1). 14–14. 43 indexed citations

Nayak, Anjuli, Guy A. Settipane, Andrew Pedinoff, et al.. (2002). Effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. Annals of Allergy Asthma & Immunology. 89(3). 271–278. 78 indexed citations

Meltzer, Eli O., B.Lauren Charous, William W. Busse, et al.. (2000). Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray. Journal of Allergy and Clinical Immunology. 106(4). 630–637. 117 indexed citations

10.

Salmun, Luis M., Jerry Herron, Christopher Banfield, et al.. (2000). The pharmacokinetics, electrocardiographic effects, and tolerability of loratadine syrup in children aged 2 to 5 years. Clinical Therapeutics. 22(5). 613–621. 35 indexed citations

11.

Kaiser, Harold B., Charles H. Banov, David I. Bernstein, et al.. (1998). Comparative Efficacy and Safety of Once-Daily Versus Twice-Daily Loratadine-Pseudoephedrine Combinations Versus Placebo in Seasonal Allergic Rhinitis. American Journal of Therapeutics. 5(4). 245–252. 13 indexed citations

12.

Nathan, Robert A., K. B. Nolop, Francis M. Cuss, & Richard Lorber. (1997). A Comparison of Double-Strength Beclomethasone Dipropionate (84 μg) MDI With Beclomethasone Dipropionate (42 μ) MDI in the Treatment of Asthma. CHEST Journal. 112(1). 34–39. 16 indexed citations

13.

Skoner, David P., Howard Boltansky, Roger H. Kobayashi, et al.. (1996). Extended-Release Albuterol in the Treatment of 6- to 12-Year-Old Asthmatic Children. Annals of Allergy Asthma & Immunology. 76(5). 462–468. 3 indexed citations

14.

Prenner, Bruce M., Paul Chervinsky, Frank C. Hampel, et al.. (1996). Double-strength beclomethasone dipropionate (84 μg/spray) aqueous nasal spray in the treatment of seasonal allergic rhinitis. Journal of Allergy and Clinical Immunology. 98(2). 302–308. 24 indexed citations

15.

Berkowitz, Robert, David G. Tinkelman, Judith Marcoux, et al.. (1995). Conversion from Twice-to Once-Daily Extended-Release Theophylline Treatment in Patients with Reversible Airway Obstruction. Journal of Asthma. 32(4). 275–284. 2 indexed citations

16.

Hébert, Jean‐Louis, et al.. (1992). Onset of action of loratadine and placebo and other efficacy variables in patients with seasonal allergic rhinitis.. PubMed. 14(2). 268–75. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact